Literature DB >> 7523449

Hyper IgM syndrome associated with defective CD40-mediated B cell activation.

M E Conley1, M Larché, V R Bonagura, A R Lawton, R H Buckley, S M Fu, E Coustan-Smith, H G Herrod, D Campana.   

Abstract

Recent studies show that most patients with X-linked hyper IgM syndrome have defects in the gene for CD40 ligand. We evaluated 17 unrelated males suspected of having X-linked hyper IgM syndrome. Activated T cells from 13 of the 17 patients failed to bind a soluble CD40 construct. In these patients, the sequence of CD40 ligand demonstrated mutations. By contrast, T cells from the remaining four patients exhibited normal binding to the CD40 construct. Sequencing of the cDNA for CD40 ligand from these patients did not show mutations. The possibility that hyper IgM syndrome in these four patients was due to abnormalities in the B cell response to CD40-mediated signals was examined. Peripheral blood lymphocytes were stimulated with anti-CD40 alone, IL4 alone or anti-CD40 plus IL4. In comparison with B cells from controls or patients with hyper IgM syndrome and mutant CD40 ligand, B cells from the patients with hyper IgM syndrome and normal CD40 ligand were defective in their ability to secrete IgE (P < 0.02) or express activation markers, CD25 and CD23 (P < 0.02) in response to stimulation with anti-CD40. The failure of these B cells to respond to CD40-mediated activation could not be attributed to a generalized deficiency in B cell activation because IL4 induced normal up-regulation of CD23 and CD25 expression. These findings indicate that hyper IgM syndrome may result from defects in expression of CD40 ligand by activated T cells or defects in CD40-mediated signal transduction in B cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523449      PMCID: PMC295267          DOI: 10.1172/JCI117476

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Identification of a source of biologically active CD40 ligand.

Authors:  R J Armitage; T A Sato; B M Macduff; K N Clifford; A R Alpert; C A Smith; W C Fanslow
Journal:  Eur J Immunol       Date:  1992-08       Impact factor: 5.532

2.  Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes.

Authors:  P Lane; A Traunecker; S Hubele; S Inui; A Lanzavecchia; D Gray
Journal:  Eur J Immunol       Date:  1992-10       Impact factor: 5.532

3.  Mechanism of antigen-driven selection in germinal centres.

Authors:  Y J Liu; D E Joshua; G T Williams; C A Smith; J Gordon; I C MacLennan
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

4.  Anti-CD45 inhibition of human B cell proliferation depends on the nature of activation signals and the state of B cell activation. A study with anti-IgM and anti-CDw40 antibodies.

Authors:  M F Gruber; J M Bjorndahl; S Nakamura; S M Fu
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

5.  Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Authors:  E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 6.  Immunodeficiency with hyper-IgM (HIM).

Authors:  L D Notarangelo; M Duse; A G Ugazio
Journal:  Immunodefic Rev       Date:  1992

7.  Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.

Authors:  J Banchereau; P de Paoli; A Vallé; E Garcia; F Rousset
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

8.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

9.  A cell culture system that enhances mononuclear cell IgE synthesis induced by recombinant human interleukin-4.

Authors:  J L Claassen; A D Levine; R H Buckley
Journal:  J Immunol Methods       Date:  1990-02-09       Impact factor: 2.303

10.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.

Authors:  D Hollenbaugh; L S Grosmaire; C D Kullas; N J Chalupny; S Braesch-Andersen; R J Noelle; I Stamenkovic; J A Ledbetter; A Aruffo
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  19 in total

1.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 2.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients.

Authors:  Bandar K Al-Saud; Zobaida Al-Sum; Hanadi Alassiri; Abdulaziz Al-Ghonaium; Saleh Al-Muhsen; Hasan Al-Dhekri; Rand Arnaout; Osama Alsmadi; Esteban Borrero; Asm'a Abu-Staiteh; Faisal Rawas; Hamoud Al-Mousa; Abbas Hawwari
Journal:  J Clin Immunol       Date:  2013-11       Impact factor: 8.317

Review 4.  Hyper IgM syndrome: two mutations distinguish HIM.

Authors:  T M Foy; S R Masters; R J Noelle
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 5.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Respiratory Complications in Patients with Hyper IgM Syndrome.

Authors:  Bobak Moazzami; Reza Yazdani; Gholamreza Azizi; Fatemeh Kiaei; Mitra Tafakori; Mohammadreza Modaresi; Rohola Shirzadi; Seyed Alireza Mahdaviani; Mahsa Sohani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2019-06-11       Impact factor: 8.317

7.  Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100.

Authors:  Cindy Eunhee Lee; David A Fulcher; Belinda Whittle; Rochna Chand; Nicole Fewings; Matthew Field; Daniel Andrews; Christopher C Goodnow; Matthew C Cook
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 8.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

9.  Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Authors:  L E Leiva; J Junprasert; D Hollenbaugh; R U Sorensen
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

10.  A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.

Authors:  Q Lin; J Rohrer; R C Allen; M Larché; J M Greene; A O Shigeoka; R A Gatti; D C Derauf; J W Belmont; M E Conley
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.